These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38258760)

  • 1. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Becker M; Ivanov M; Bhat S
    Ann Pharmacother; 2024 Oct; 58(10):1054-1063. PubMed ID: 38258760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
    Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
    Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
    Vermeire S; Sands BE; Peyrin-Biroulet L; D'Haens GR; Panés J; Yarur AJ; Wolf DC; Ritter T; Schreiber S; Woolcott JC; Modesto I; Keating M; Shan K; Wu J; Chiorean MV; Baert F; Dubinsky MC; Goetsch M; Danese S; Feagan BG
    J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38877972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
    Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
    J Crohns Colitis; 2024 Aug; 18(8):1270-1282. PubMed ID: 38613425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
    Jairath V; Rubin DT; Verstockt B; Çekin AH; Abreu MT; Lees CW; Fellmann M; Woolcott JC; Crosby C; Wu J; Bhattacharjee A; Herman D; Gu G; Siegmund B
    Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38899786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    Vermeire S; Chiorean M; Panés J; Peyrin-Biroulet L; Zhang J; Sands BE; Lazin K; Klassen P; Naik SU; Cabell CH; Sandborn WJ
    J Crohns Colitis; 2021 Jun; 15(6):950-959. PubMed ID: 33475734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program.
    Regueiro M; Siegmund B; Yarur AJ; Steinwurz F; Gecse KB; Goetsch M; Bhattacharjee A; Wu J; Green J; McDonnell A; Crosby C; Lazin K; Branquinho D; Modesto I; Abreu MT
    J Crohns Colitis; 2024 May; ():. PubMed ID: 38700040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etrasimod for the treatment of ulcerative colitis.
    Wils P; Peyrin-Biroulet L
    Immunotherapy; 2023 Apr; 15(5):311-321. PubMed ID: 36789612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2024 Feb; ():10600280241229742. PubMed ID: 38344998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.
    Suilik HA; Jaber F; Abuelazm M; Ramadan A; Elzeftawy MA; Elrosasy A; Youssef RA; Abdelazeem B; Hashash JG; Farraye FA; Ghoz H
    Inflamm Res; 2024 Feb; 73(2):183-198. PubMed ID: 38153524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrasimod: First Approval.
    Shirley M
    Drugs; 2024 Feb; 84(2):247-254. PubMed ID: 38388871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
    Silverberg JI; Bissonnette R; Kircik L; Murrell DF; Selfridge A; Liu K; Ahluwalia G; Guttman-Yassky E
    J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1366-1374. PubMed ID: 36695074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
    Bencardino S; D'Amico F; Faggiani I; Bernardi F; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
    J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
    Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
    Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Solitano V; Vuyyuru SK; MacDonald JK; Zayadi A; Parker CE; Narula N; Peyrin-Biroulet L; Danese S; Feagan BG; Singh S; Ma C; Jairath V
    J Crohns Colitis; 2023 Nov; 17(11):1800-1816. PubMed ID: 37317532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
    Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
    Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.